Table 1:
Patient demographics and clinical characteristics:
| Features | All SLE | HC* | L+N+ | L+N− | L−N− |
|---|---|---|---|---|---|
| Number | 83 | 25 | 28 | 29 | 26 |
| Age, mean ± SD | 13.6 ± 2.3 | 14.2 ± 2 | 15 ± 3 | 15 ± 3 | 16 ± 3 |
| Females, N (%) | 72 (86.7) | 30 (100) | 33 (92) | 13 (87) | 27 (82%) |
| Race | |||||
| Hispanic, N (%) | 47 (57) | 14 | 16 | 17 | 14 |
| African American, N (%) | 23 (28) | 4 | 7 | 10 | 6 |
| Caucasian, N (%) | 7 (8.4) | 11 | 2 | 1 | 4 |
| Asian, N (%) | 4 (4.8) | 1 | 1 | 1 | 2 |
| Mixed, N (%) | 2 (2.4) | 0 | 2 | 0 | 0 |
| SLE disease duration, median (IQR*), mos | 6.8 (0.2–30) | - | 0.3 (0.1–2.6) | 0.7 (0.2–17) | 28 (16–55) |
| SLEDAI*, median (IQR) | 5 (0–10) | 0 | 12 (8–22) | 5 (4–11) | 0 (0–3) |
| Historical SLE Class (%) | |||||
| Neuropsychiatric | 12% | 0% | 18% | 10% | 9% |
| Musculoskeletal | 60% | 0% | 64% | 57% | 56% |
| Kidney disorder | 61% | 0% | 100% | 17% | 58% |
| Mucocutanous | 52% | 0% | 57% | 58% | 38% |
| Serositis | 22% | 0% | 32% | 14% | 21% |
| Hematological | 83% | 0% | 86% | 72% | 85% |
*
HC: healthy controls; L+N+ active SLE with active nephritis; L+N- active non-renal SLE; L-N- SLE in clinical remission; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; IQR:
Interquartile range.